MAPK3 and schwannoma: This study represents one of the first evidence for signaling of PrPC via RPSA with the engagement of downstream Erk1/2, PI3K/Akt and FAK signaling pathways to control survival, proliferation and cell–matrix–adhesion in schwannoma cells, suggesting PrPC and its interactor as potential therapeutic targets for schwannomas.